Persistent tumor mutation burden linked with therapeutic res

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy.

Related Keywords

Noushin Niknafs , Valsamo Anagnostou , Johns Hopkins , Emily Henderson , Bloomberg Kimmel Institute For Cancer Immunotherapy , Johns Hopkins Kimmel Cancer Center , Lung Cancer Precision Medicine Center , Kimmel Institute , Johns Hopkins Molecular Tumor Board , Cancer Genome Atlas , Johns Hopkins Kimmel Cancer , Immunotherapy , Biomarker , Dancer , Ancer Immunotherapy , Fell , Iagnostics , Enetic , Enome , Enomic , Head And Neck Cancer , Immune Response , Immune System , Lung Cancer , Medicine , Melanoma , Mesothelioma , Utation , Neck , Ncology , Mh , Precision Medicine , Research , Humor ,